Loading clinical trials...
Loading clinical trials...
UCDCC#271: A Phase I/II Trial of Epacadostat (Indolamine 2,3 Dioxygenase Inhibitor), Intralesional SD101 (Toll-receptor 9 Agonist), and Radiotherapy in Patients With Advanced Solid Tumors and Lymphoma
Conditions
Interventions
epacadostat
SD-101
+1 more
Locations
1
United States
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Start Date
January 17, 2018
Primary Completion Date
February 24, 2020
Completion Date
April 8, 2020
Last Updated
February 1, 2022
NCT05529069
NCT06337318
NCT06898450
NCT07388563
NCT05139017
NCT06263491
Lead Sponsor
University of California, Davis
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions